SCHEMBL20154017

SCHEMBL20154017

CC(C)(C)OCC(=O)NCCCCCCCCCCOc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ STAT3 P40763 2/20 0.65
▸ CRBN Q96SW2 10/20 0.64
▸ DDB1 Q16531 7/20 0.64
▸ HDAC1 Q13547 5/20 0.62
▸ HDAC6 Q9UBN7 5/20 0.62
▸ HDAC3 O15379 2/20 0.62
▸ HDAC2 Q92769 2/20 0.62
▸ HDAC4 P56524 1/20 0.62
▸ NCOR2 Q9Y618 1/20 0.62
▸ CCNK O75909 1/20 0.55
▸ CDK12 Q9NYV4 1/20 0.55
▸ CDK2 P24941 1/20 0.55
▸ CDK9 P50750 1/20 0.55
▸ CDK5 Q00535 1/20 0.55
▸ GSK3B P49841 2/20 0.54
▸ BRD4 O60885 1/20 0.54
▸ ESR1 P03372 2/20 0.53
▸ ESR2 Q92731 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20154019 1.00 STAT3 (0.65) STAT3CRBNDDB1HDAC1HDAC6
SCHEMBL20153966 0.99 STAT3 (0.65) STAT3CRBNDDB1HDAC1HDAC6
SCHEMBL20154000 0.96 STAT3 (0.69) STAT3CRBNDDB1HDAC1HDAC6
SCHEMBL20154012 0.96 STAT3 (0.69) STAT3CRBNDDB1HDAC1HDAC6
SCHEMBL20153963 0.95 STAT3 (0.70) STAT3CRBNDDB1HDAC1HDAC6
SCHEMBL20154008 0.93 STAT3 (0.65) STAT3CRBNDDB1HDAC1HDAC6
SCHEMBL20153993 0.92 STAT3 (0.65) STAT3CRBNDDB1HDAC1HDAC6
SCHEMBL20148928 0.91 CRBN (0.63) STAT3CRBNDDB1HDAC1HDAC6
SCHEMBL20153979 0.91 CRBN (0.63) STAT3CRBNDDB1HDAC1HDAC6
SCHEMBL23584014 0.91 CRBN (0.69) STAT3CRBNDDB1HDAC1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10464925-B2 Methods to induce targeted protein degradation through bifunctional molecules DANA-FARBER CANCER INSTITUTE, INC. (US) 2019-11-05 — — US disclosed
US-20180134684-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES DANA-FARBER CANCER INSTITUTE, INC. (US) 2018-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10464925-B2 Methods to induce targeted protein degradation through bifunctional molecules CRBN, MDM2, MYCBP STAT3 2989/4885CRBN 1/4885DDB1 113/4885
US-20180134684-A1 METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES CRBN, MDM2, MYCBP STAT3 2989/4885CRBN 1/4885DDB1 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback